ministration to human patients, wherein the pharmaceutical
formulation comprises fulvestrant in solution, 10%weight ethanol per volume of formulation, 15 % weight of benzyl benzoate
per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45 mgml-1
of fulvestrant.
2. The use as claimed in claim 1, whereas the total amount of fulvestrant dissolved in the formulation is 250 mg and the total
volume of the formulation is 5 ml.
3. The use as claimed in claims 1 or 2, whereas the formulation is
present in a syringe